Central selective acetylcholinesterase inhibitor with neurotrophic activity: Structure-activity relationships of TAK-147 and related compounds

Current Medicinal Chemistry

Volumn 7, Issue 3, 2000, Pages 341-354

  Ishihara, Yuji ^a   Goto, Giichi ^a   Miyamoto, Masaomi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; ZANEPEZIL;

ALZHEIMER DISEASE; BRAIN METABOLISM; CHOLINERGIC NERVE CELL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; EXPERIMENTAL ANIMAL; LEARNING; MEMORY; MONOAMINE METABOLISM; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034121289     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/0929867003375272     Document Type: Review

References (31)

1. (a) Katzman, R. N. Engl. J. Med., 1986, 315, 964.
2. (b) Selkoe, D.J. Ann. Rev. Neurosci. 1994, 17, 489.
3. (a) Whitehouse, P. J.; Price, D. L.; Struble, R. G.; Clark, A. W.; Coyle, J. T.; DeLong, M. R. Science, 1982, 215,1237.
4. (b) Coyle, J. T.; Price, D. L.; DeLong, M. R. Science, 1983, 279, 1184.
5. (c) Price, D. L.; Borchelt, D. R.; Sisodia, S. S. Proc. Natl. Acad. Sci. USA, 1993, 90, 6381.
6. (a) Davis, P.; Maloney, A. J. F. Lancet, 1977, ii, 1403.
7. (b) Perry, E. K.; Tomlinson, B. E.; Blessed, G.; Bergmann, K.; Gibson, P. H.; Perry, R. H. Br. Med. J., 1978, 2, 1457.
8. (a) Bondareff, W.; Mountjoy, C. Q.; Roth, M. Neurobiology, 1982, 32, 164.
9. (b) Curcio, C. A.; Kemper, T. J. Neuropathol. Exp. Neurol., 1984, 43, 359.
10. (c) Mann, D. M.; Yates, P. O.; Marcyniuk, B. J. Neurol. Neurosurg. Psychiatry, 1984, 47, 201.
11. (d) Gottfries, C. G. Psychopharmacology, 1985, 86, 245.
12. (e) Yamamoto, T.; Hirano, A. Ann. Neurol., 1985, 17, 573.
13. Perry, E. K.; Curtis, M.; Pick, D. J. J. Neurol. Neurosurg. Psychiatry, 1985, 48, 413.
14. (a) Drachman, D. A. Neurology, 1977, 27, 783.
15. (b) Sitaram, N.; Weingartner. H.; Gillin, J. C. Science, 1978, 201, 274.
16. (a) Bartus, R. T.; Dean, R. L.; Beer, B.; Lippa, A. S. Science, 1982, 277, 408.
17. (b) Aigner, T. G.; Mitchell, S. J.; Aggleton, J. P.; DeLong, M. R.; Struble, R. G.; Price, D. L.; Wenk, G. L.; Mishkin, M. Psychopharmacology. 1987, 92, 292.
18. (c) Miyamoto, M.; Hirai, K.; Takahashi, H.; Kato, K.; Nishiyama, M.; Okada, H. Nagaoka, A. Eur. J. Pharmacol., 1993, 233, 181.
19. (a) Bartus, R. T.; Dean, L. D. III; Beer, B.; Lippa, A. S. Science, 1982, 277, 408.
20. (b) Perry, E. K. Br. Med. Bull., 1986, 42, 63.
21. (c) Jenden, D. J. Prog. Brain Res., 1990, 84, 479.
22. (d) John, V.; Lieberburg, I.; Thorsett, E. D. Ann. Rep. Med. Chem., 1993, 23, 197.
23. Giacobini, E. Jpn. J. Pharmacol., 1997, 74, 225.
24. Benzi, G.; Moretti, A. Eur. J. Pharmacol., 1998, 346, 1.
25. Hobbiger, F. Handb. Exp. Pharmak., 1976, 42, 487.
26. Quinn, D. M. Chem. Rev., 1987, 87, 955.
27. (a) Mooser, G.; Sigman, D. S. Biochemistry, 1974, 73, 2299.
28. (b) Taylor, P.; Lappi, S. Biochemistry, 1975, 14, 1989.
29. (c) Radic, Z.; Reiner, E.; Taylor, P. Mol. Pharmacol., 1991, 39, 98.
30. Sussman, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Science, 1991, 253, 872.
31. Ishihara, Y.; Kato, K.; Goto, G. Chem. Pharm. Bull., 1991, 39, 3225.